Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970787 | 0.84 | SLC6A3 (0.56) | SLC6A3SIGMAR1ACHEOPRM1HTR1A | |
| SCHEMBL1269135 | 0.83 | OPRL1 (0.58) | SIGMAR1ACHEOPRM1MEN1KMT2A | |
| SCHEMBL24093313 | 0.80 | SMN1; SMN2 (0.56) | SLC6A3SIGMAR1ACHEOPRM1HTR1A | |
| SCHEMBL21726765 | 0.80 | SLC6A3 (0.59) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL3566447 | 0.79 | SLC6A3 (0.54) | SLC6A3SIGMAR1ACHEOPRM1MEN1 | |
| SCHEMBL16684766 | 0.77 | OPRL1 (0.51) | SIGMAR1MEN1KMT2A | |
| SCHEMBL15470506 | 0.77 | SLC6A3 (0.51) | SLC6A3SIGMAR1OPRM1OPRD1 | |
| SCHEMBL13150782 | 0.76 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEMEN1KMT2A | |
| SCHEMBL14407778 | 0.76 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEMEN1KMT2A | |
| SCHEMBL6056974 | 0.76 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |